Review articles

Hirsh, J., et al.

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
Chest, 2001. 119(1 Suppl): p. 64S-94S.
Description: A comprehensive review of heparin and low molecular weight heparins.

Hirsh, J., et al.

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
Chest, 2001. 119(1 Suppl): p. 8S-21S.
Description: A comprehensive review of oral anticoagulants

Coller, B.S.

Anti-GPIIb/IIIa drugs: current strategies and future directions.
Thrombosis & Haemostasis, 2001. 86(1): p. 427-43.
Description: A definitive review of a rapidly changing class of agents.

Original articles

Bern, M.M., et al.

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.
Annals of Internal Medicine, 1990. 112(6): p. 423-8.

Heaton, D.C., D.Y. Han, and I. Inder

Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis.
Internal Medicine Journal, 2002. 32: p. 84-88.
Description: Prospective trials indicating that very low doses of warfarin can prevent thrombosis associated with central venous catheters (this is controversial), as well as during chemotherapy for metastatic breast cancer.

Levine, M., et al.

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
New England Journal of Medicine, 1996. 334(11): p. 677-81.

Koopman, M.M., et al.

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
New England Journal of Medicine, 1996. 334(11): p. 682-7.
Description: Prospective trials demonstrating that home subcutaneous low molecular heparin therapy is as safe and effective as hospital based intravenous unfractionated heparin therapy for proximal deep vein thrombosis.

Anonymous

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators.
New England Journal of Medicine, 1997. 337(10): p. 657-62.

Simonneau, G., et al.

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
New England Journal of Medicine, 1997. 337(10): p. 663-9.
Description: Prospective trials demonstrating that fixed dose subcutaneous low molecular weight heparin is as effective and safe as intravenous adjusted dose unfractionated heparin for initial therapy of symptomatic venous thromboembolism.

Return to Table of Contents